The three companies have been operating as one full service CRO following the acquisition of Vince & Associates in 2013 and the opening of Algorithme Pharma USA in 2014. Since then, the teams have been leveraging their extensive background within early clinical research to provide a full-service offering, including complex phase I/IIa pharmacology capabilities and support services to the global biopharmaceutical industry.
"This visual change is a strategic move to bring to the market one unified look that better represents our seamless internal processes and close-knit teams," said Chris Perkin, CEO of Altasciences Clinical Research.
The updated brand identity was unveiled on the company's website and can be seen at several industry conferences beginning in February 2016. With over 25 years of clinical research experience across three strategically located clinical facilities in Canada and the U.S., over 600 beds for healthy normal volunteer and patient population studies, a full range of support services and a unique focus on early phase drug development, Altasciences Clinical Research is the largest early phase clinical CRO in North America.
"Altasciences' mission remains the same, which is to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service. We will achieve this by continuously improving our customer relationships and range of services as well as by creating an environment that provides value for our customers, respect for our volunteers and growth for our employees," said Perkin.